Global Medical Partners

Leveraging the "National 9 Articles" special policies of Hainan Boao Lecheng Pilot Zone, we connect you to Japan's largest private medical group, China's #1 hematology brand, the world's largest stem cell bank, and other world-class medical resources.

Boao Super Hospital

Boao Lecheng, Hainan · China

JCI Accredited Special Policy Zone 10+ Academician Teams

A Grade-III general hospital in China's only "medical special zone." Led by Academician Li Lanjuan with 10+ academician teams. Under special State Council policies, it can use international cutting-edge drugs and devices years before mainland approval. Completed 50+ "first in China" procedures in ophthalmology, cardiology, ENT, oncology, and stem cell therapy.

Specialties: Ophthalmology, Cardiology, ENT, Oncology, Stem Cell Therapy, Health Screening

Xinwakai Medical Corporation

Tokyo · Japan

Japan's Largest Private Medical Group JCI Accredited

Japan's largest private medical conglomerate, operating Shinwa Medical Resort (Yachiyo & Kashiwanoha), Koto Medical Tower (7 floors, 4000m²), and multiple university-affiliated hospitals. Through JIMC (Japan International Medical Center), we offer premium Japanese health screening, anti-aging, critical care, and regenerative medicine services.

Specialties: Health Screening, Anti-Aging, Cancer Early Detection, Regenerative Medicine, Immunotherapy

Lu Daopei Medical Group

Beijing / Hebei / Shanghai · China

China's #1 Hematology Brand Founded by Academician Lu Daopei Global Leader in HSCT Volume

Founded by Academician Lu Daopei, the "Father of Asian Bone Marrow Transplantation." China's largest hematology medical service provider with 4 hospitals. Annual allogeneic HSCT volume ranks among the highest globally, with advanced CAR-T immunotherapy programs.

Specialties: Hematology, HSCT, CAR-T Immunotherapy, Bone Marrow Transplant

Ruijin Hospital Hainan

Boao Lecheng, Hainan · China

National Medical Center Most Lecheng Projects 9+ Approved Technologies

Affiliated with Shanghai Jiao Tong University School of Medicine. Leads the most biomedical technology projects in Lecheng, including airway basal stem cell therapy for COPD/bronchiectasis/ILD, RPE65 gene therapy for inherited retinal dystrophy, and iPSC-derived neural progenitor cells for ALS.

Specialties: Respiratory Medicine, Stem Cell Therapy, Gene Therapy, Endocrinology, ALS

West China Lecheng Hospital

Boao Lecheng, Hainan · China

West China Brand AAV Gene Therapy 8+ Approved Technologies

West China Hospital (Sichuan University) extension in Lecheng. Offers hemophilia A gene therapy (AAV vector, ¥680K/dose), heart failure MSC therapy, liver cirrhosis MSC therapy, melanoma DC vaccine, and endothelial progenitor cell therapy for critical limb ischemia.

Specialties: Gene Therapy, Cardiovascular, Cancer Immunotherapy, Hepatology, Hemophilia

Hubei Stem Cell Bank

Wuhan, Hubei · China

World's Largest Cell Bank AABB International Standard 37 Patents

Founded by Academician Lu Daopei and approved by Hubei Provincial S&T Department. The world's largest cell preservation bank, built to AABB standards. Using -196°C liquid nitrogen cryopreservation, cells maintain 95%+ viability after 35 years. Offers immune cell and MSC (umbilical cord, dental pulp, adipose) storage.

Services: Immune Cell Storage, Umbilical Cord MSC Storage, Dental Pulp MSC Storage, Adipose MSC Storage

Boao Lecheng International Medical Tourism Pilot Zone

China's only "medical special zone," established by the State Council in 2013. Under four franchise policies — Franchise Medical Care, Franchise Research, Franchise Operation, and Franchise International Medical Tourism — Lecheng can legally use international cutting-edge drugs, devices, and biomedical technologies before they are approved elsewhere in China, bypassing the typical 5-10 year registration wait.

Franchise Medical Care

Use overseas-approved drugs, devices & technologies not yet registered in China

Franchise Research

Real-world data studies to accelerate domestic regulatory approval

Franchise Operation

Wholly foreign-owned medical institutions & fast-tracked international expert approval

Franchise Intl. Medical Tourism

86-country visa-free entry; 560K+ medical tourism visits in 2026

29 approved biomedical technology projects covering stem cell therapy, immunotherapy, and gene therapy — all with transparent public pricing (¥36K-680K), serving 400+ patients.

Key projects: Knee osteoarthritis MSC (¥36K/session), COPD airway stem cell (¥150K/session), Hemophilia A gene therapy (¥680K/dose), Autologous NK anti-cancer (¥49.8K/session), iPSC for ALS, DC vaccine for tumors.

Need Help Finding the Right Hospital and Specialist?

Our medical advisor team will match you with the most suitable partner hospital and treatment plan based on your health needs — completely free of charge.

Book a Consultation